PT1059921E - Utilizacao de compostos macrolitos para o tratamento de sdra - Google Patents

Utilizacao de compostos macrolitos para o tratamento de sdra

Info

Publication number
PT1059921E
PT1059921E PT99937870T PT99937870T PT1059921E PT 1059921 E PT1059921 E PT 1059921E PT 99937870 T PT99937870 T PT 99937870T PT 99937870 T PT99937870 T PT 99937870T PT 1059921 E PT1059921 E PT 1059921E
Authority
PT
Portugal
Prior art keywords
compounds
treatment
macrolite
ards
utilization
Prior art date
Application number
PT99937870T
Other languages
English (en)
Inventor
Itsuo Nagatomi
Tadatsura Koshika
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of PT1059921E publication Critical patent/PT1059921E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99937870T 1998-03-06 1999-03-04 Utilizacao de compostos macrolitos para o tratamento de sdra PT1059921E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP2231A AUPP223198A0 (en) 1998-03-06 1998-03-06 New use

Publications (1)

Publication Number Publication Date
PT1059921E true PT1059921E (pt) 2003-11-28

Family

ID=3806495

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99937870T PT1059921E (pt) 1998-03-06 1999-03-04 Utilizacao de compostos macrolitos para o tratamento de sdra

Country Status (15)

Country Link
US (1) US6333334B1 (pt)
EP (1) EP1059921B1 (pt)
JP (1) JP3367105B2 (pt)
KR (1) KR100395571B1 (pt)
CN (1) CN1133429C (pt)
AT (1) ATE244008T1 (pt)
AU (1) AUPP223198A0 (pt)
BR (1) BR9908796A (pt)
CA (1) CA2322027C (pt)
DE (1) DE69909257T2 (pt)
DK (1) DK1059921T3 (pt)
ES (1) ES2196840T3 (pt)
HK (1) HK1036406A1 (pt)
PT (1) PT1059921E (pt)
WO (1) WO1999044597A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
RU2470623C2 (ru) * 2006-09-29 2012-12-27 Инфа С.А. Упаковка с фармацевтической композицией и комплект для внутривенного введения
JP2010514790A (ja) * 2006-12-28 2010-05-06 リメリック バイオファーマ, インコーポレイテッド 治療処置のための方法および組成物
ES2435197T3 (es) * 2007-01-10 2013-12-16 Board Of Regents, The University Of Texas System Administración mejorada de composiciones de fármacos inmunosupresores para la administración por vía pulmonar
CN101011414B (zh) * 2007-01-29 2010-07-21 褚福明 一种肺脑合剂药物
KR20100051829A (ko) * 2007-07-31 2010-05-18 리머릭 바이오파르마 인코오포레이티드 인산화된 피론 유사체 및 방법
CN101810633B (zh) * 2010-03-31 2011-12-14 湖北丝宝药业有限公司 地红霉素在制备治疗慢性非感染性呼吸道疾病药物的用途
GB201212773D0 (en) * 2012-07-18 2012-08-29 Ucl Business Plc Vascular remodelling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent

Also Published As

Publication number Publication date
EP1059921A2 (en) 2000-12-20
DE69909257D1 (de) 2003-08-07
CN1133429C (zh) 2004-01-07
CA2322027C (en) 2009-05-12
BR9908796A (pt) 2000-10-31
ATE244008T1 (de) 2003-07-15
CN1292695A (zh) 2001-04-25
EP1059921B1 (en) 2003-07-02
AUPP223198A0 (en) 1998-04-02
WO1999044597A3 (en) 1999-12-29
US6333334B1 (en) 2001-12-25
JP2001520682A (ja) 2001-10-30
DE69909257T2 (de) 2004-02-19
HK1036406A1 (en) 2002-01-04
WO1999044597A2 (en) 1999-09-10
DK1059921T3 (da) 2003-10-27
JP3367105B2 (ja) 2003-01-14
KR100395571B1 (ko) 2003-08-21
ES2196840T3 (es) 2003-12-16
KR20010041046A (ko) 2001-05-15
CA2322027A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
PT1056454E (pt) Utilizacao de compostos macrolido para o tratamento do glaucoma
ES2176600T3 (es) Derivado de la propiofenona y procedimientos para su preparacion.
PT1169370E (pt) Solucoes de poliuretano contendo unidades estruturais de alcoxissilano.
NO962187L (no) Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav
HUP0103147A3 (en) Pharmaceutical composition comprising glp1 and their use for the treatment of functional dyspepsia and/or irritable bowel syndrome
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
BR0110024A (pt) Derivados de ecteinascidina antitumorais
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
BR9709654A (pt) Derivados da tiazolidina-2,4-diona substituídos seus processos de obtenção e as composições farmacêuticas que os contêm
PT1059921E (pt) Utilizacao de compostos macrolitos para o tratamento de sdra
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
BR9908427A (pt) Composições farmacêuticas e uso das mesmas
EE200300064A (et) Farmatseutiline kompositsioon C. pneumoniae pooltpõhjustatud infektsioonide raviks ja/või ennetamiseks, mahekompositsioon ja nende kasutamine
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
DE60116106D1 (de) Benzofuran derivate und ihre verwendung als antibakterielle wirkstoffe
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o
AU2002252134A1 (en) Methods of treating irritable bowel syndrome and functional dyspepsia
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
NO882030D0 (no) Fremgangsmaate til fremstilling av hydrasinderivater til bruk som antihypertensivt middel.
NO982562L (no) Sammensetning for behandling av smerte
DE69114707T2 (de) Neue alpha-glukosidaseinhibitoren.
NO20030801L (no) Aminoalkenylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte for deres fremstilling og preparater inneholdende de samme